Galapagos backpedals on separation plans, CEO Paul Stoffels exits early
A month ago, former AbbVie and Neumora executive Henry Gosebruch was named the CEO of Galapagos' planned spinout, which would be handed €2.45 billion to hunt for drug candidates and build a ...
